New Funds Extend Chi-Med’s Runway But HK Listing Still Planned
Launches, Pipeline Progress Seen Adding Value
Chi-Med opted to raise modest funds in the US to extend its cash runway ahead of a ‘big year’ but still intends to pursue a larger Hong Kong listing at an appropriate time, its CEO tells Scrip.
You may also be interested in...
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Prices of direct acting hepatitis C drugs are down by 85% in China, with cancer and antidiabetes therapy costs cut by 65% and drug makers are rushing to celebrate. Scrip delves into the considerations behind the low prices and whether industry's excitement is a bit premature.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.